PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)

被引：0
|
作者：
Chiney, M. S. [1 ]
Polepally, A. R. [1 ]
Nader, A. M. [1 ]
Dufek, M. B. [1 ]
Klein, C. E. [1 ]
Ng, J. W. [1 ]
Shebley, M. [1 ]
机构：
[1] Abbvie, N Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-022
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [31] LEVERAGING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING AND CLINICAL DATA TO PREDICT DRUG-DRUG INTERACTIONS (DDI) OF AVAPRITINIB AND GUIDE DOSE ADJUSTMENTS
    Suram, A.
    Powers, J.
    Dave, N.
    Kim, S.
    Baker, J.
    Ankrom, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S106 - S106
  • [32] Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin
    Park, Min-Ho
    Shin, Seok-Ho
    Byeon, Jin-Ju
    Lee, Gwan-Ho
    Yu, Byung-Yong
    Shin, Young G.
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2017, 21 (01): : 107 - 115
  • [33] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING FOR PREDICTION OF COMPLEX DRUG-DRUG INTERACTIONS (DDIs) INVOLVING OATPIB1-MEDIATED UPTAKE AND CYTOCHROME P450 (CYP) METABOLISM AND MULTIPLE INHIBITORS.
    Yeo, K. Rowland
    Jamei, M.
    Aarabi, M.
    Rostami-Hodjegan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S47 - S48
  • [34] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING FOR PREDICTION OF THE DRUG-DRUG INTERACTION (DDI) BETWEEN PAROXETINE AND TERBINAFINE IN A JAPANESE POPULATION.
    Yeo, K. Rowland
    Barter, Z.
    Almond, L.
    Rostami-Hodjegan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S119 - S120
  • [35] Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Medi-ated Drug Absorption, Clearance and Drug-drug Interactions
    Taskar, Kunal S.
    Harada, Isobel
    Alluri, Ravindra, V
    CURRENT DRUG METABOLISM, 2021, 22 (07) : 523 - 531
  • [36] INVESTIGATING TRANSPORTER-MEDIATED DRUG-DRUG INTERACTIONS (DDIS) OF DASATINIB USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL.
    Chang, M.
    Bathena, S.
    Christopher, L.
    Shen, H.
    Roy, A.
    Leil, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S7 - S7
  • [37] Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
    Liu, Hongrui
    Yu, Yiqun
    Guo, Nan
    Wang, Xiaojuan
    Han, Bing
    Xiang, Xiaoqiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR PREDICTION OF CYP-MEDIATED DRUG-DRUG INTERACTIONS INVOLVING ETHINYLESTRADIOL.
    Ezuruike, U.
    Humphries, H.
    Dickins, M.
    Neuhoff, S.
    Gardner, I.
    Rowland-Yeo, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S66 - S66
  • [39] Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug-Drug Interactions, Pediatric Patients, and Pregnancy and Lactation
    Liu, Xiaomei I.
    Leong, Ruby
    Burckart, Gilbert J.
    Dallmann, Andre
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (03): : 323 - 333
  • [40] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
    Nina Hanke
    José David Gómez-Mantilla
    Naoki Ishiguro
    Peter Stopfer
    Valerie Nock
    Pharmaceutical Research, 2021, 38 : 1645 - 1661
12345